Life Sciences

  • June 18, 2026

    RFK Jr. Urges 1st Circ. To Reinstate His Vaccine Advisers

    U.S. Health Secretary Robert F. Kennedy Jr. told the First Circuit a Boston federal judge's decision to freeze his vaccine committee appointments lacks a legal foundation and has left the government paralyzed when it comes to vaccine policy.

  • June 18, 2026

    DEA Picks Only Pot Foes To Join Rescheduling Hearings

    The U.S. Drug Enforcement Administration on Thursday announced its selection of interested parties to participate in upcoming administrative hearings on a proposal to reclassify marijuana to a less restrictive status, each of whom is understood to oppose marijuana rescheduling.

  • June 18, 2026

    Cannabis World Cheers Justices' Gun Rights Ruling

    Cannabis industry stakeholders on Thursday largely applauded the U.S. Supreme Court's unanimous decision finding that a ban on gun ownership for drug users is unconstitutional as applied to a person who regularly uses marijuana.

  • June 18, 2026

    Goodwin, Latham Lead Biotech Kardigan's $400M IPO

    Venture-backed Kardigan Inc., a biotechnology firm developing therapies for cardiovascular diseases, hit the public markets on Thursday after raising $400 million in its initial public offering.

  • June 18, 2026

    Gibson Dunn Hires Ropes & Gray Health Regulatory Atty In DC

    Gibson Dunn & Crutcher LLP has hired a former Ropes & Gray LLP partner who works on a myriad of health regulatory and drug pricing matters, advising pharmaceutical manufacturers, investors and other entities on those issues, the firm announced Thursday.

  • June 18, 2026

    Patent Claims On Novartis Unit Drug Invalid, Del. Judge Says

    A Delaware federal judge has cleared radiopharmaceutical companies of allegations they infringed claims in various patents owned by a French unit of Novartis after finding that all of those claims were invalid.

  • June 18, 2026

    Pharma Co. Says Machine Breakdown Triggered Coverage

    A pharmaceutical company said its insurers improperly denied coverage to fix an eye dropper bottle filling machine, arguing the machine's breakdown caused extensive interruption to business activities that would trigger the policy, according to a complaint removed to California federal court Wednesday.

  • June 18, 2026

    High Court Bars Federal Review Of State Court Appeals

    The U.S. Supreme Court ruled Thursday that a legal doctrine designed to curtail duplicative litigation prevents parties who lose in state court from appealing in federal district court even if the state case is still pending.

  • June 18, 2026

    Justices Allow Gun Rights For Marijuana User

    U.S. Supreme Court justices ruled Thursday that the federal government cannot bar a drug user from owning guns, saying that the prosecution of a Texas man accused of owning a gun while being a marijuana user was inconsistent with the Second Amendment right to bear arms.

  • June 17, 2026

    Eli Lilly Urges Full Fed. Circ. To Scrap Teva's $177M IP Win

    Eli Lilly & Co. urged the full Federal Circuit Wednesday to review a panel ruling that upheld Teva's $177 million jury verdict on headache drug patents, arguing that the panel's decision runs afoul of the justices' Amgen holding and "opens a truck-sized hole in enablement and written description law."

  • June 17, 2026

    Hikma Ruling Raises Patent Pleading Bar Beyond Drug Cases

    The U.S. Supreme Court's decision this month that shut down a patent suit against Hikma Pharmaceuticals USA over a drug using a so-called skinny label could also make it more challenging to plead induced infringement in cases involving other technologies, attorneys say.

  • June 17, 2026

    Grocery Chain Says Aon Put $40M In Opioid Coverage At Risk

    Supermarket chain Giant Eagle on Wednesday hit insurance brokerage firm Aon with claims in Pennsylvania federal court that it jeopardized $40 million in coverage allegedly owed to the chain for settlement and defense costs in opioid litigation.

  • June 17, 2026

    Sen. Committee Clears Drug Disclosure, Biosimilar Bills

    The U.S. Senate Committee on Health, Education, Labor and Pensions on Wednesday cleared two bills for full Senate review, tackling the gap between health and patent oversight agencies, and the need for more interchangeable biosimilars.

  • June 17, 2026

    ITC, Masimo Tell Full Fed. Circ. To Skip Apple Watch Review

    Masimo Corp. and the U.S. International Trade Commission have pushed back on Apple's request for full Federal Circuit rehearing of a panel decision finding an older version of the Apple Watch infringes Masimo's patents, saying Wednesday the case isn't exceptional enough for such scrutiny.

  • June 17, 2026

    Embecta Investor Suit Says Pen Needle Weakness Was Hidden

    Medical device company Embecta Corp. and two of its executives were hit with a proposed class action Wednesday, alleging they misled investors about the sales performance of the company's pen needles, which are often used by patients with diabetes.

  • June 17, 2026

    Del. Court Invalidates Patent Claims In Bioscience Co. Row

    A federal magistrate judge in Delaware on Wednesday found that claims in three molecular labeling patents held by Parse Biosciences Inc. were invalid, months after he found that they weren't infringed by Scale Biosciences Inc.

  • June 17, 2026

    Fed. Circ. Affirms No Block On Stryker Spine Device In IP Fight

    The Federal Circuit on Wednesday agreed with a lower court decision rejecting Boston Scientific Corp.'s request to temporarily block Stryker Corp. from launching a back pain device, saying Stryker made a good enough case that it didn't cause physicians to infringe a patent on the treatment.

  • June 17, 2026

    Glenmark Pharma Beats Suit Over Recalled Cholesterol Drugs

    A New Jersey federal judge Wednesday tossed a proposed class action that accused drugmaker Glenmark Pharmaceuticals of falsely representing that its statin cholesterol drugs were safe and effective despite a recall over its manufacturing practices, saying plaintiff consumers' lack of actual economic or physical injury meant they couldn't sue.

  • June 17, 2026

    Syngenta, Chevron Bids To Move Paraquat Cases Opposed

    Plaintiffs alleging they developed Parkinson's disease from an herbicide asked a Philadelphia judge to block bids by Syngenta and Chevron to move the cases out of the city's mass tort system, arguing that the companies already tried that and failed.

  • June 17, 2026

    HHS Urges DC Court To Toss AbbVie 340B Audit Challenge

    A D.C. federal court should toss a suit by AbbVie challenging the U.S. Department of Health and Human Services' interpretation of who qualifies as a "patient" for audits under the federal 340B drug discount program, HHS said in a motion, arguing the court lacks jurisdiction.

  • June 16, 2026

    Sanofi Sued Over Qunol CoQ10 'Superior Absorption' Claims

    Sanofi-Aventis US deceives customers into believing its Qunol liquid CoQ10 supplements have "superior absorption" advantages compared to regular CoQ10 products despite scientific testing that shows otherwise and prior legal action that barred it from making similar efficacy claims, alleges a proposed class action filed Monday in New Jersey federal court.

  • June 16, 2026

    Eli Lilly Settles Mounjaro TM Suit Against Seattle Area Clinics

    Eli Lilly has agreed to drop a lawsuit accusing two Washington clinics of ripping off its trademarks for the weight loss drugs Mounjaro and Zepbound, according to a voluntary dismissal motion filed in federal court on Monday, almost two weeks after a judge rejected a resolution proposed by the parties. 

  • June 16, 2026

    Del. Judge Won't Touch Jury's $83M Diagnostics IP Verdict

    A Delaware federal judge on Tuesday upheld a jury's 2023 verdict finding that Guardant Health Inc. should pay TwinStrand Biosciences Inc. $83.4 million for willfully infringing diagnostic patents, refusing to overturn or enhance the award.

  • June 16, 2026

    SEC Settles Insider Trading Suit Against Biotech Investor

    The U.S. Securities and Exchange Commission announced on Tuesday that a Texas-based investor will pay over $240,000 to settle the agency's claims he improperly traded stocks on insider information by buying shares of a public biotech firm ahead of its 2020 merger with a privately held biotechnology company.

  • June 16, 2026

    Cigna Loses Privilege Bid Due To 'Inaccurate, Redundant' Log

    Cigna "improperly asserted privilege" over hundreds of documents that three laboratories sought as part of the discovery process in federal payment litigation in Connecticut, according to a special master appointed by the judge in the consolidated cases.

Expert Analysis

  • Unpacking Key Themes From NY's New Healthcare Strategy

    Author Photo

    New York Gov. Kathy Hochul's 2026 State of the State agenda, read together with the state's fiscal year 2027 executive budget, reflect a clear framework to utilize Medicaid as the state's operating platform for healthcare reform, say attorneys at Sheppard.

  • 5 Different AI Systems Raise Distinct Privilege Issues

    Author Photo

    A New York federal court’s recent U.S. v. Heppner decision, holding that a defendant’s use of Claude was not privileged, only addressed one narrow artificial intelligence system, but lawyers must recognize that the spectrum of AI tools raises different confidentiality and privilege questions, says Heidi Nadel at HP.

  • Opinion

    AI-Assisted Arbitration Needs Safeguards To Ensure Fairness

    Author Photo

    As tribunals and arbitral institutions increasingly use artificial intelligence tools in their decision-making processes, ​​​​​​​clear disclosure standards and procedural safeguards are necessary to ensure that efficiency gains do not erode the fairness principles on which arbitration depends, says Alexander Lima at Wesco International.

  • Trans Care Enforcement Landscape Is Evolving Quickly

    Author Photo

    The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.

  • Series

    Playing Piano Makes Me A Better Lawyer

    Author Photo

    Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.

  • 3 Cases Highlight SEC Distinction Between Exec, Co. Liability

    Author Photo

    Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.